Mr Christopher William Ogden MB BS MS FRCSEd FRCSEng FRCSUrol FEBU

www.roboticprostatesurgery.co.uk

www.urologists.co.uk

Innovator and leader in Urology

Chris Ogden was appointed Consultant Urologist in 1996 at Northwick Park and St Marks Hospital. He became clinical lead before the Genome project came to fruition and developed a lab-based project in the Northwick Park Institute of Medical research exploring the relationship of genetic changes and prostate and bladder cancer. This led to multiple MD theses, with the urology trainees going on to be leading Urology consultants and the patenting of the PAX2 gene in prostate cancer through Imperial College.

He was one of a handful of Urologists to pioneer the open perineal prostatectomy approach to prostate cancer, far superior to the open abdominal approach in terms of trauma, blood loss and cosmesis, together with a short hospital stay and quicker return to normal activities and full urinary continence. In 1997, he approached two colleagues from disparate trusts to establish the first group private practice in any medical speciality, based at the Princess Grace. From the founding three and a turnover of £150000, the practice evolved over twenty years to a partnership of eleven consultants and a turnover of around £3,000,000 a year. In 2003, he was one of the first to explore HIFU for the treatment of prostate cancer and a year later was appointed to St Mary's Hospital, who had installed the first Da Vinci Robot in the UK. With no established clinical practice, he put together a group of Urologists from different hospital trusts to become the first group of surgeons in the UK to be recognised as able to perform robotic radical prostatectomy. At the time, many were sceptical of the technology and warned of potential grave consequences from adopting the device for radical treatment of prostate cancer. Since there are more than 500 Da Vinci robots now in fifth generation machines and thousands of robotic surgeons in many different specialities, with radical robotic prostatectomy being the gold standard for the radical removal of prostate cancer. He was the first UK urologist to present the UK experience to the fledgling European Robotic Urological Society and the American Urological Society; also presenting the first one hundred, then 500, robotic cases with outcome to the British Urological Society; as well as the only clinical comparison between whole gland HIFU and Robotic prostatectomy, the two novel competing technologies at that time. This comparison showed that whole gland HIFU delivered the perfect trifecta outcome in a third of patients, but that overall robotic surgical removal had the edge. As a result, HIFU treatment had to wait until the development of MRI to visualise prostate cancer to target the cancer with HIFU, evolving the concept focal therapy for prostate cancer. He has been contributing to the initial and, more recently, most comprehensive multicentre studies to demonstrate the therapeutic role of Focal therapy for prostate, continuing to offer his patients this procedure where appropriate.

After his first twenty cases in the NHS, he performed the first Radical Robotic Prostatectomy in the private sector (on a patient at the Princess Grace Hospital), which was published by the medical correspondent Dr Stutaford in the Times.

When he was appointed to Chelsea and Westminster in 2000 to join Mr Michael Dinneen, with their complementary skills, they founded a strong urology practice, Urologists Limited. Their practice has a strong and loyal referral base in Kensington and Chelsea, as well as attracting referrals worldwide from the coverage of the pioneering urological treatments in the national press and on TV.

Mr Ogden continues to innovate. Over the last year, he teamed up with Dr Kouk of the Cleveland clinic to perform the first Radical Robotic Perineal Prostatectomy in Europe, written up in Urology News at the time. Since, he has performed around twenty cases and is due to present his outcomes (the first series in Europe) to the European Urological Association in July, at the annual congress. He is one of only three surgeons in the world performing the procedure. It has exciting prospects, with the introduction of the latest Da Vinci robot, the SP. The application of his skill in perineal open surgery, learnt as a travelling fellow to Duke University Carolina and developed as a newly appointed consultant, married with the longest and largest (around 3000 cases performed) experience of radical prostatectomy in the UK gives him the potential to improve the outcomes for patients undergoing radical prostatectomy.

Consultant Posts Held

Consultant Uro-Oncologist the Royal Marsden Hospital, London. Current Appointment on the highest local clinical Excellence award.

Dec 2006 – to date

Mr Ogden was recruited by the Royal Marsden Hospital to set up a new robotic urological service using the Da Vinci S laparoscopic robot. He rapidly built up high volume robotic prostatectomy program with other specialities coming online. In 2009, he was the first robotic surgeon to receive the prestigious Innovation Award in Robotics In the UK, in recognition of over 1,000 patients treated with excellent published outcomes. Mr Ogden is the first surgeon in the UK and one of only a few surgeons worldwide to receive this prestigious award.

Consultant Urologist Chelsea and Westminster and St Mary's hospitals.

Jan 2002 – Dec 2006

Mr Ogden was appointed clinical lead in General Surgery and Urology. He developed his skills in Laparoscopic surgery including nephrectomy. In November 2004 he put together the first team in the UK to be certified in Radical Robotic Prostatectomy using the Da Vinci System. Since then he has performed around 3000 radical robotic prostatectomies, the most performed by a urologist in the UK.

In 2003, he was one of the first Urologists in the UK involved in the groundbreaking treatment in the UK using High Intensity Focused Ultrasound to treat prostate cancer. He presented the only comparison of whole gland HIFU and radial robotic prostatectomy for the treatment of prostate cancer.

Consultant Urologist Northwick park and St Mark's Hospitals.

Jan 1996-Dec 2001

Mr Ogden was appointed to his first Consultant Urologist post in 1995 at a busy district general hospital and postgraduate teaching centre at Northwick Park and St Mark's. He became clinical lead in Urology and he performed common urological procedures such as TURP and complex endourological procedures such as ureteroscopy for stone extraction. Mr Ogden developed the use of the perineal approach for radical prostatectomy and the

Studer orthotopic bladder replacement following radical cystectomy, including females. He developed a combined perineal and abdomino-perineal approach for the treatment of locally advanced rectal cancer involving the prostate, a pioneering operation. As well as his clinical work, Mr Ogden successfully funded and supervised four research fellows leading to the award of their MD theses. His research was identifying the re-expression of highly specific developmental genes involved in the early development of the embryo and the urogenital tract. His team found expression of PAX2 in prostate cancer and PAX5 in bladder cancer. Mr Ogden explored the possible link between Human endogenous retrovirus encoded in the human genome and prostate cancer and role of Dentritic cells in bladder cancer; in particular in their role in BCG therapy with the aim of understanding the immunological response with the hope of developing more specific treatments. Clinical trials and evaluation included the monoclonal targeting of prostate cancer, a phase II open-label trial to evaluate intravenous 3622W94 monoclonal antibody for the treatment of metastatic prostate cancer: the evaluation of primary and metastatic cancer of the prostate using radioimmunoscintigraphy with Indium-111 labelled CYT-356.

Medical Training

Urology Visiting Fellow sponsored by the Royal College of Surgeons 1995

Professor De Kernion, University of California, Los Angeles,
Dr Donald Skinner, University of Southern California, Los Angeles
Dr Patrick Walsh, John Hopkins Hospital, Baltimore
Dr J Paulson, Duke University, North Carolina

Grants obtained since Mr Ogden's appointment as consultant:

Royal College of Surgeons of England research fellowship, 1997
Royal College of Surgeons of England research fellowship,1998
Prostate research campaign, 1999
BMA research grant June 1999
The Prostate Research Campaign UK, 1991
The Peel Medical Research Trust, 2000 The
Berkeley Fellowship, 2000
The Mason Medical Research Foundation, 2000
The British Urological Foundation Research Scholarship, 2001
The Ralph Shackman Trust, 2001
The Ralph Shackman Trust, 2002

Senior Registrar Urology West London training scheme between Charing Cross, St Mary's, St Helier and the Royal Marsden Hospitals Aug 1993- July1995

Visiting Lecturer to Japan, Professor Yoshoio, Chairman of the Japanese Urological Association and Dept of Urology at the University of Tokyo and Professor Osamu Yoshida Kyoto University School of Medicine Nov-Dec 1992

Research Registrar Urology Charing Cross Hospital Jan 1992 – Dec1992

Registrar Urology Charing Cross and Hammersmith Jan 1991 – July 1993

Registrar general and vascular training rotation between the Hammersmith and the West Middlesex University Hospital from Jan 1989 – Dec 1990

Qualifications

MB BS University of London 1984
FRCS Edinburgh 1989
FRCS England 1990
MS University of London 1993 FRCS Urology 199FEBU 1996
Medical School: Charing Cross and Westminster 1979-1984
School: Haileybury and Imperial Services College 1972-1978

Publications

Robotic assisted radical perineal prostatectomy with the Hudson approach: initial European experience with 12 cases
Bolton EM, Russell B, So C, Ogden CW
Journal of European Urology 2020 accepted for publication

Robotic assisted perineal prostatectomy: descriptive technique of the inaugural case in the UK
Jonathan Patrick Noël, Bradley Russell, Christopher William Ogden and Jihad Kaouk
Urology News, Volume 23, Issue 2, January/February 2019

The evolutionary history of lethal metastatic prostate cancer.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC; ICGC Prostate Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS.Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347. Epub 2015 Apr 1.PMID: 25830880

Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, Dennis N, Merson S, Leongamornlert D, Zamora J, Corbishley C, Thomas S, Nik-Zainal S, O'Meara S, Matthews L, Clark J, Hurst R, Mithen R, Bristow RG, Boutros PC, Fraser M, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S, Greenman C, Berney D, Hazell S, Livni N; ICGC Prostate Group, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah NC, Gnanapragasam V, Voet T, Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton MR, Whitaker HC, McDermott U, Brewer DS, Neal DE.Nat Genet. 2015 Apr;47(4):367-372. doi: 10.1038/ng.3221. Epub 2015 Mar 2.PMID: 25730763

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA.Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.PMID: 29662167

A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, Hosking-Jervis F, Hindley RG, Lewi H, McCartan N, Moore CM, Nigam R, Ogden C, Persad R, Shah K, van der Meulen J, Virdi J, Winkler M, Emberton M, Ahmed HU.Eur Urol. 2018 Oct;74(4):422-429. doi: 10.1016/j.eururo.2018.06.006. Epub 2018 Jun 28.PMID: 29960750.Clinical Trial.

Mutational signatures of ionizing radiation in second malignancies.
Behjati S, Gundem G, Wedge DC, Roberts ND, Tarpey PS, Cooke SL, Van Loo P, Alexandrov LB, Ramakrishna M, Davies H, Nik-Zainal S, Hardy C, Latimer C, Raine KM, Stebbings L, Menzies A, Jones D, Shepherd R, Butler AP, Teague JW, Jorgensen M, Khatri B, Pillay N, Shlien A, Futreal PA, Badie C; ICGC Prostate Group, McDermott U, Bova GS, Richardson AL, Flanagan AM, Stratton MR, Campbell PJ.Nat Commun. 2016 Sep 12;7:12605. doi: 10.1038/ncomms12605.PMID: 27615322

Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.
Camacho N, Van Loo P, Edwards S, Kay JD, Matthews L, Haase K, Clark J, Dennis N, Thomas S, Kremeyer B, Zamora J, Butler AP, Gundem G, Merson S, Luxton H, Hawkins S, Ghori M, Marsden L, Lambert A, Karaszi K, Pelvender G, Massie CE, Kote-Jarai Z, Raine K, Jones D, Howat WJ, Hazell S, Livni N, Fisher C, Ogden C, Kumar P, Thompson A, Nicol D, Mayer E, Dudderidge T, Yu Y, Zhang H, Shah NC, Gnanapragasam VJ; CRUK-ICGC Prostate Group, Isaacs W, Visakorpi T, Hamdy F, Berney D, Verrill C, Warren AY, Wedge DC, Lynch AG, Foster CS, Lu YJ, Bova GS, Whitaker HC, McDermott U, Neal DE, Eeles R, Cooper CS, Brewer DS.PLoS Genet. 2017 Sep 25;13(9):e1007001. doi: 10.1371/journal.pgen.1007001. eCollection 2017 Sep.PMID: 28945760

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D,

Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA.Version 2. Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15.PMID: 24484606.Clinical Trial.

Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.
Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O'Meara S, Anderson E, Maddison M, Gamble S, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, Veer LV, Caldas C, Desmedt C, Sotiriou C, Aparicio S, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL, Van de Vijver M, Vincent-Salomon A, Van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ; ICGC Breast Cancer Group; ICGC Bone Cancer Group; ICGC Prostate Cancer Group.Science. 2014 Aug 1;345(6196):1251343. doi: 10.1126/science.1251343.PMID: 25082706

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.Br J Cancer. 2016 Apr 12;114(8):945-52. doi: 10.1038/bjc.2016.50.PMID: 26964030

Multiple loci on 8q24 associated with prostate cancer susceptibility.
Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Sawyer E, Lophatananon A; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, Donovan JL, Hamdy FC, Neal DE, Eeles RA, Easton DF.Nat Genet. 2009 Oct;41(10):1058-60. doi: 10.1038/ng.452. Epub 2009 Sep 20.PMID: 19767752

Identification of new genetic risk factors for prostate cancer.
Guy M, Kote-Jarai Z, Giles GG, Al Olama AA, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL; UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jameson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF, Eeles RA.Asian J Androl. 2009 Jan;11(1):49-55. doi: 10.1038/aja.2008.18. Epub 2008 Dec 1.PMID: 19050691.Review.

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.
Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF.Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20.PMID: 19767753

Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry.
Lovegrove CE, Peters M, Guillaumier S, Arya M, Afzal N, Dudderidge T, Hosking-Jervis F, Hindley RG, Lewi H, McCartan N, Moore CM, Nigam R, Ogden C, Persad R, Virdi J, Winkler M, Emberton M, Ahmed HU, Shah TT, Minhas S.BJU Int. 2020 Jun;125(6):853-860. doi: 10.1111/bju.15004. Epub 2020 Feb 11.PMID: 31971335

Multivariate modelling of prostate cancer combining magneticresonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters.
Riches SF, Payne GS, Morgan VA, Dearnaley D, Morgan S, Partridge M, Livni N, Ogden C, deSouza NM.Eur Radiol. 2015 May;25(5):1247-56. doi: 10.1007/s00330-014-3479-0. Epub 2015 Mar 7.PMID: 25749786

Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.
Dickinson L, Arya M, Afzal N, Cathcart P, Charman SC, Cornaby A, Hindley RG, Lewi H, McCartan N, Moore CM, Nathan S, Ogden C, Persad R, van der Meulen J, Weir S, Emberton M, Ahmed HU.Eur Urol. 2016 Oct;70(4):668-674. doi: 10.1016/j.eururo.2016.02.054. Epub 2016 Mar 4.PMID: 26951947Clinical Trial.

Robotic prostatectomy: the first UK experience.
Mayer EK, Winkler MH, Aggarwal R, Karim O, Ogden C, Hrouda D, Darzi AW, Vale JA.Int J Med Robot. 2006 Dec;2(4):321-8. doi: 10.1002/rcs.113.PMID: 17520650Review.

Port site hernias following robot-assisted laparoscopic prostatectomy.
Hotston MR, Beatty JD, Shendi K, Ogden C.J Robot Surg. 2009 Mar;3(1):49-51. doi: 10.1007/s11701-009-0133-y. Epub 2009 Mar 3.PMID: 27628454

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ, Kraft P, Thun MJ, Ingles S, Chanock S, Albanes D, Hayes RB, Neal DE, Hamdy FC, Donovan JL, Pharoah P, Schumacher F, Henderson BE, Stanford JL, Ostrander EA, Sorensen KD, Dörk T, Andriole G, Dickinson JL, Cybulski C, Lubinski J,

Spurdle A, Clements JA, Chambers S, Aitken J, Gardiner RA, Thibodeau SN, Schaid D, John EM, Maier C, Vogel W, Cooney KA, Park JY, Cannon-Albright L, Brenner H, Habuchi T, Zhang HW, Lu YJ, Kaneva R, Muir K, Benlloch S, Leongamornlert DA, Saunders EJ, Tymrakiewicz M, Mahmud N, Guy M, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English DR, Wahlfors T, Tammela TL, Klarskov P, Nordestgaard BG, Røder MA, Tybjærg-Hansen A, Bojesen SE, Travis R, Canzian F, Kaaks R, Wiklund F, Aly M, Lindstrom S, Diver WR, Gapstur S, Stern MC, Corral R, Virtamo J, Cox A, Haiman CA, Le Marchand L, Fitzgerald L, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Meyer A, Serth J, Yeager M, Berndt SI, Marthick JR, Patterson B, Wokolorczyk D, Batra J, Lose F, McDonnell SK, Joshi AD, Shahabi A, Rinckleb AE, Ray A, Sellers TA, Lin HY, Stephenson RA, Farnham J, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators/ British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators, The Australian Prostate Cancer BioResource; PRACTICAL Consortium.Nat Genet. 2011 Jul 10;43(8):785-91. doi: 10.1038/ng.882.PMID: 21743467.Clinical Trial.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS– Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai Z, Easton DF.Nat Genet. 2013 Apr;45(4):385-91, 391e1-2. doi: 10.1038/ng.2560.PMID: 23535732

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.
Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T,

Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; Australian Prostate Cancer Bioresource; PRACTICAL Consortium, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA.Hum Mol Genet. 2013 Jan 15;22(2):408-15. doi: 10.1093/hmg/dds425. Epub 2012 Oct 12.PMID: 23065704

A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study.
Dickinson L, Ahmed HU, Kirkham AP, Allen C, Freeman A, Barber J, Hindley RG, Leslie T, Ogden C, Persad R, Winkler MH, Emberton M; INDEX Study Group.Contemp Clin Trials. 2013 Sep;36(1):68-80. doi: 10.1016/j.cct.2013.06.005. Epub 2013 Jun 14.PMID: 23774040 Clinical Trial.

Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, Dennis N, Merson S, Leongamornlert D, Zamora J, Corbishley C, Thomas S, Nik-Zainal S, Ramakrishna M, O'Meara S, Matthews L, Clark J, Hurst R, Mithen R, Bristow RG, Boutros PC, Fraser M, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S, Greenman C, Berney D, Hazell S, Livni N; ICGC Prostate Group, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah NC, Gnanapragasam V, Voet T, Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton MR, Whitaker HC, McDermott U, Brewer DS, Neal DE.Nat Genet. 2015 Jun;47(6):689. doi: 10.1038/ng0615-689b.PMID: 26018901No abstract available.

Multiple newly identified loci associated with prostate cancer susceptibility.
Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL; UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF.Nat Genet. 2008 Mar;40(3):316-21. doi: 10.1038/ng.90. Epub 2008 Feb 10.PMID: 18264097

High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.

Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M.Br J Cancer. 2009 Jul 7;101(1):19-26. doi: 10.1038/sj.bjc.6605116. Epub 2009 Jun 9.PMID: 19513068,Clinical Trial.

Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer?
Beatty JD, Islam S, North ME, Knight SC, Ogden CW.BJU Int. 2004 Dec;94(9):1377-83. doi: 10.1111/j.1464-410X.2004.05176.x.PMID: 15610124

Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, Flohr P, Christmas T, Thompson A, Parker M, Shepherd C, Stenman UH, Marchbank T, Playford RJ, Woodhouse C, Ogden C, Fisher C, Kovacs G, Corbishley C, Jameson C, Norman A, De-Bono J, Bjartell A, Eeles R, Cooper CS.BJU Int. 2009 May;103(9):1256-69. doi: 10.1111/j.1464-410X.2008.08200.x. Epub 2008 Nov 25.PMID: 19040532

Exclusive amplification of cDNA template (EXACT) RT-PCR to avoid amplifying contaminating genomic pseudogenes.
Smith RD, Ogden CW, Penny MA.Biotechniques. 2001 Oct;31(4):776-8, 780, 782. doi: 10.2144/01314st03.PMID: 11680707

Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.
Jhavar S, Reid A, Clark J, Kote-Jarai Z, Christmas T, Thompson A, Woodhouse C, Ogden C, Fisher C, Corbishley C, De-Bono J, Eeles R, Brewer D, Cooper C.J Mol Diagn. 2008 Jan;10(1):50-7. doi: 10.2353/jmoldx.2008.070085. Epub 2007 Dec 28.PMID: 18165275

Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: A proposed standard for the conduct of therapy.
Illing RO, Leslie TA, Kennedy JE, Calleary JG, Ogden CW, Emberton M.BJU Int. 2006 Dec;98(6):1187-92. doi: 10.1111/j.1464-410X.2006.06509.x.PMID: 17125476

Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer.
Feneley MR, Jan H, Granowska M, Mather SJ, Ellison D, Glass J, Coptcoat M, Kirby RS, Ogden C, Oliver RT, Badenoch DF, Chinegwundoh FI, Nargund VH, Paris AM, Britton KE.Prostate Cancer Prostatic Dis. 2000 Jul;3(1):47-52. doi: 10.1038/sj.pcan.4500390.PMID: 12497162

Expression of the developmental and oncogenic PAX2 gene in human prostate cancer.
Khoubehi B, Kessling AM, Adshead JM, Smith GL, Smith RD, Ogden CW.J Urol. 2001 Jun;165(6 Pt 1):2115-20. doi: 10.1097/00005392-200106000-00080.PMID: 11371938

Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes.
Adshead JM, Kessling AM, Ogden CW.Br J Urol. 1998 Oct;82(4):503-12. doi: 10.1046/j.1464-410x.1998.00767.x.PMID: 9806178Review.No abstract available.

The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation.
Adshead JM, Ogden CW, Penny MA, Stuart ET, Kessling AM.BJU Int. 1999 Jun;83(9):1039-44. doi: 10.1046/j.1464-410x.1999.00052.x.PMID: 10368252

The Klippel-Trenaunay syndrome associated with renal artery aneurysm.

Ogden CW, Jackson JE.Br J Urol. 1993 May;71(5):617-8. doi: 10.1111/j.1464-410x.1993.tb16043.x.PMID: 8518879No abstract available.

Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction.
Ogden CW, Reddy P, Johnson H, Ramsay JW, Carter SS.Lancet. 1993 Jan 2;341(8836):14-7. doi: 10.1016/0140-6736(93)92482-9.PMID: 7678047Clinical Trial.

Morbidity and the impact on daily activities associated with catheter drainage after acute urinary retention.
Khoubehi B, Watkin NA, Mee AD, Ogden CW.BJU Int. 2000 Jun;85(9):1033-6. doi: 10.1046/j.1464-410x.2000.00666.x.PMID: 10848690

A 12-month study of the placebo effect in transurethral microwave thermotherapy.
De Wildt MJ, Hubregtse M, Ogden C, Carter SS, Debruyne FM, De la Rosette JJ.Br J Urol. 1996 Feb;77(2):221-7. doi: 10.1046/j.1464-410x.1996.82511.x.PMID: 8800890Clinical Trial.

Intratracheal thyroid tissue presenting with stridor. A case report.
Ogden CW, Goldstraw P.Eur J Cardiothorac Surg. 1991;5(2):108-9. doi: 10.1016/1010-7940(91)90009-9.PMID: 2018653

The prediction of clinical outcome from transurethral microwave thermotherapy by pressure-flow analysis: a European multicenter study.
Tubaro A, Carter SS, de la Rosette J, Höfner K, Trucchi A, Ogden C, Miano L, Valenti M, Jonas U, Debruyne F.J Urol. 1995 May;153(5):1526-30.PMID: 7536261Clinical Trial.

Multiple frequent recurrences in superficial transitional cell carcinoma of the bladder: is survival compromised by a conservative management strategy?
Hrouda D, Ogden C, Morris SB, Wanendeya N, Fisher C, Woodhouse CR.Br J Urol. 1997 May;79(5):726-30. doi: 10.1046/j.1464-410x.1997.00118.x.PMID: 9158510Clinical Trial.

Clinical response to transurethral microwave thermotherapy is thermal dose dependent.
Devonec M, Ogden C, Perrin P, St Clair Carter S.Eur Urol. 1993;23(2):267-74. doi: 10.1159/000474611.PMID: 7683985